The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | MRD-driven addition of ibrutinib to venetoclax for CLL
Lydia Scarfò, MD, Vita-Salute San Raffaele University, Milan, Italy, discusses the results of the monotherapy and combination phases of the Phase II IMPROVE study, investigating minimal residual disease (MRD)-driven treatment intensification by sequential addition of ibrutinib to venetoclax for relapsed/refractory chronic lymphocytic leukemia (CLL). The sequential MRD-guided approach was feasible and achieved deeper responses in the majority of patients who did not achieve undetectable MRD after venetoclax treatment alone. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Dr Lydia Scarfò, MD, has participated in advisory boards for AbbVie, AstraZeneca, Gilead and Janssen.
